Archive for April, 2008
An article published in The Lancet Neurologyrecommends a phase III study for the drug tarenflurbil, amedication given to patients with mild Alzheimer’s disease (AD). Thephase II study found that patients who took 800 mg of tarenflurbiltwice daily had better functional ability results than patients takingplacebo.
More: continued here
The 23rd Colloque Medecine et Recherche of La Fondation Ipsen dedicated to the Alzheimer series was held in Paris on 28 April 2008. Entitled “Intracellular Traffic and Neurodegenerative Disorders” this meeting gathered fourteen leading researchers focused on the intracellular world.
More: continued here
Milan Fiala, MD, UCLA Orthopedic Hospital, has been chosen as the recipient of the 2008 Alzheimer Award presented by the Journal of Alzheimer’s Disease in recognition of his outstanding work, “Phagocytosis of amyloid-beta and inflammation: Two faces of innate immunity in Alzheimer’s disease” by M. Fiala, D.H. Cribbs, M. Rosenthal and G. Bernard (July 2007, JAD 11(4): 457-63).
More: continued here
An article published in the April issue of the Journal of Alzheimer’s Disease presents a detailed characterization of a new drug discovery tool for Alzheimer’s disease. It demonstrates that an abnormal form of tau protein, as it occurs in Alzheimer’s disease, can be produced in very simple cell models in an unambiguous way. Most importantly, it also shows an example of a chemical compound, found in nature, which is highly effective to completely suppress the abnormal changes of tau.
More: continued here
An influential group of MPs is calling on the Government to stop the dangerous over-prescribing of antipsychotic drugs to people with dementia. Up to 105,000 people with dementia are given the drugs inappropriately, according to expert predictions in the new All-Party Parliamentary Group (APPG) on Dementia report, ‘Always A Last Resort’, published recently.
More: continued here
Alzheimer Scotland welcomes this landmark review which endorses the policy of free personal care for older people. Jim Jackson, Chief Executive, Alzheimer Scotland, said: “There is no cure for dementia, but the provision of personal care is as necessary for the health and well being of people with this devastating illness as medical treatment is for cancer patients.
More: continued here
In studies of human brain cells, the widely-used anesthetic desflurane does not contribute to increased production of amyloid-beta protein; however, when combined with low oxygen conditions, it can produce more of this Alzheimer’s associated protein.Over 200 million people undergo surgery each year, and there has been concern that anesthetic use may contribute to Alzheimer’s and other brain disorders.
More: continued here
Hispanic and black caregivers are more likely than other ethnic groups to misinterpret symptoms of Alzheimer’s disease as normal signs of aging, according to a recent survey by the Alzheimer’s Foundation of America, HealthDay/Washington Post reports.
More: continued here
JADO Technologies GmbH, the leading developer of RAFT intervention therapeutics, has announced he publication of a paper in Science demonstrating a potential novel strategy for therapeutic intervention in Alzheimer’s and other diseases by targeting discrete sub-compartments in the cell membrane (RAFTS). The study conducted by JADO scientists together with several academic collaborators will appear in the April 25, 2008 issue of the magazine.
More: continued here
The most common form of dementia, Alzheimer’s disease, and a relatively rare hereditary form of dementia, frontotemporal dementia with parkinsonism-17, share a common pathology: Both are the result of an overaccumulation of tau proteins, which form tangled lesions in the brain’s neurons and eventually lead to the collapse of the brain cells responsible for memory.
More: continued here





